Inflammatory Myopathies.
Journal
Continuum (Minneapolis, Minn.)
ISSN: 1538-6899
Titre abrégé: Continuum (Minneap Minn)
Pays: United States
ID NLM: 9509333
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
entrez:
20
12
2022
pubmed:
21
12
2022
medline:
23
12
2022
Statut:
ppublish
Résumé
This article outlines the salient clinical, serologic, electrophysiologic, imaging, and histopathologic findings and treatment options for the idiopathic inflammatory myopathies, including those related to immune checkpoint inhibitors and SARS-CoV-2. The classification of idiopathic inflammatory myopathies has improved with the integration of myositis-specific antibodies and histopathologic findings. Characteristic features of immune checkpoint inhibitor-related myositis have been identified, allowing early recognition and treatment of the syndrome. The COVID-19 pandemic has had a profound impact on the care of patients with idiopathic inflammatory myopathies, and several mechanisms of virus-related muscle injury have been proposed. A comprehensive evaluation including clinical examination, EMG, imaging, antibody testing, muscle biopsy, and cancer screening, when appropriate, can lead to an earlier accurate diagnosis and an individualized treatment approach for patients with idiopathic inflammatory myopathies.
Identifiants
pubmed: 36537973
doi: 10.1212/CON.0000000000001179
pii: 00132979-202212000-00007
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1643-1662Informations de copyright
Copyright © 2022 American Academy of Neurology.
Références
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts. N Engl J Med 1975;292(7):344–347. doi:10.1056/NEJM197502132920706
doi: 10.1056/NEJM197502132920706
Allenbach Y, Benveniste O, Goebel HH, Stenzel W. Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol 2017;43(1):62–81. doi:10.1111/nan.12380
doi: 10.1111/nan.12380
Allenbach Y, Mammen AL, Benveniste O. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018;28(1):87–99. doi:10.1016/j.nmd.2017.09.016
doi: 10.1016/j.nmd.2017.09.016
van der Meulen MFG, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003;61(3):316–321. doi:10.1212/wnl.61.3.316
doi: 10.1212/wnl.61.3.316
Vilela V, Prieto-González S, Milisenda JC, Selva-o´callaghan A, Grau JM. Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up. Rheumatol Int 2015;35(5):915–920.
Goyal N. Inclusion Body Myositis. Continuum (Minneap Minn) 28(6, Muscle and Neuromuscular Junction Disorders):1663–1677.
De Lorenzo R, Pinal-Fernandez I, Huang W. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology 2018;90(23). doi:10.1212/WNL.0000000000005638
doi: 10.1212/WNL.0000000000005638
Mohassel P, Landon-Cardinal O, Foley AR. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm 2018;6(1). doi:10.1212/NXI.0000000000000523
doi: 10.1212/NXI.0000000000000523
Fiorentino DF, Kuo K, Chung L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol 2015;72(3):449–455. doi:10.1016/j.jaad.2014.12.009
doi: 10.1016/j.jaad.2014.12.009
Gunawardena H, Wedderburn LR, Chinoy H. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009;60(6):1807–1814. doi:10.1002/art.24547
doi: 10.1002/art.24547
Pestronk A. Neuromuscular Disease Center website. Neuromuscular Disease Center, Washington University, St. Louis, Missouri. Accessed August 15, 2022. https://neuromuscular.wustl.edu
Sato S, Hoshino K, Satoh T. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60(7):2193–2200. doi:10.1002/art.24621
doi: 10.1002/art.24621
Nozaki K, Pestronk A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J Neurol Neurosurg Psychiatry 2009;80(8):904–908. doi:10.1136/jnnp.2008.161448
doi: 10.1136/jnnp.2008.161448
McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol 2018;14(5):290–302. doi:10.1038/nrrheum.2018.56
doi: 10.1038/nrrheum.2018.56
Ichimura Y, Matsushita T, Hamaguchi Y. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012;71(5):710–713. doi:10.1136/annrheumdis-2011-200697
doi: 10.1136/annrheumdis-2011-200697
Trallero-Araguás E, Rodrigo-Pendás JÁ, Selva-O’Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64(2):523–532. doi:10.1002/art.33379
doi: 10.1002/art.33379
Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis & Rheumatism 2006;54(11):3682–3689. doi:10.1002/art.22164
doi: 10.1002/art.22164
González-Bello Y, Garcia-Valladares I, Reyes-Pérez IV, et al. Myositis-Specific Antibodies and Myositis-Associated Antibodies in Patients With Idiopathic Inflammatory Myopathies From the PANLAR Myositis Study Group. J Clin Rheumatol 2021;27(8):e302–e306. doi:10.1097/RHU.0000000000001350
doi: 10.1097/RHU.0000000000001350
Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum 1985;28(7):796–803. doi:10.1002/art.1780280711
doi: 10.1002/art.1780280711
Betteridge ZE, Gunawardena H, Chinoy H. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis 2009;68(10):1621–1625. doi:10.1136/ard.2008.097162
doi: 10.1136/ard.2008.097162
Albayda J, Mecoli C, Casciola-Rosen L. A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol 2021;3(5):287–294. doi:10.1002/acr2.11247
doi: 10.1002/acr2.11247
Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford 2017;56(6):999–1007. doi:10.1093/rheumatology/kex021
doi: 10.1093/rheumatology/kex021
Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990;33(9):1361–1370. doi:10.1002/art.1780330908
doi: 10.1002/art.1780330908
Suzuki S, Nishikawa A, Kuwana M. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis 2015;10(61). doi:10.1186/s13023-015-0277-y
doi: 10.1186/s13023-015-0277-y
Mammen AL, Chung T, Christopher-Stine L. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63(3):713–721. doi:10.1002/art.30156
doi: 10.1002/art.30156
Dalakas MC. Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myol 2020;39(4):289–301. doi:10.36185/2532-1900-032
doi: 10.36185/2532-1900-032
Allenbach Y, Keraen J, Bouvier AM. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain 2016;139(Pt:82131–2135. doi:10.1093/brain/aww054
doi: 10.1093/brain/aww054
Zhang L, Yang H, Lei J. Muscle pathological features and extra-muscle involvement in idiopathic inflammatory myopathies with anti-mitochondrial antibody. Semin Arthritis Rheum 2021;51(4):741–748. doi:10.1016/j.semarthrit.2021.05.019
doi: 10.1016/j.semarthrit.2021.05.019
Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 2012;135(Pt 6):1767–1777. doi:10.1093/brain/aws106
doi: 10.1093/brain/aws106
Casal-Dominguez M, Pinal-Fernandez I, Derfoul A The phenotype of myositis patients with anti-Ku autoantibodies. Semin Arthritis Rheum 2021;51(4):728–734. doi:10.1016/j.semarthrit.2021.04.012
doi: 10.1016/j.semarthrit.2021.04.012
Casal-Dominguez M, Pinal-Fernandez I, Corse AM, et al. Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology 2019;92(13):e1416–e1426. doi:10.1212/WNL.0000000000007188
doi: 10.1212/WNL.0000000000007188
Sener U, Martinez-Thompson J, Laughlin RS. Needle electromyography and histopathologic correlation in myopathies. Muscle Nerve 2019;59(3):315–320. doi:10.1002/mus.26381
doi: 10.1002/mus.26381
Day JA, Bajic N, Gentili S. Radiographic patterns of muscle involvement in the idiopathic inflammatory myopathies. Muscle Nerve 2019;60(5):549–557. doi:10.1002/mus.26660
doi: 10.1002/mus.26660
Schulze M, Kötter I, Ernemann U. MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol 2009;192(6):1708–1716. doi:10.2214/AJR.08.1764
doi: 10.2214/AJR.08.1764
Greenberg SA, Pinkus JL, Pinkus GS. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57(5):664–678. doi:10.1002/ana.20464
doi: 10.1002/ana.20464
Uruha A, Nishikawa A, Tsuburaya RS. Sarcoplasmic MxA expression: a valuable marker of dermatomyositis. Neurology 2017;88(5):493–500. doi:10.1212/WNL.0000000000003568
doi: 10.1212/WNL.0000000000003568
Mescam-Mancini L, Allenbach Y, Hervier B. Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain 2015;138(Pt:92485–2492. doi:10.1093/brain/awv192
doi: 10.1093/brain/awv192
Stenzel W, Preuße C, Allenbach Y. Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 2015;84(13):1346–1354. doi:10.1212/WNL.0000000000001422
doi: 10.1212/WNL.0000000000001422
Girolamo F, Lia A, Annese T. Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. Muscle Nerve 2019;60(3):315–327. doi:10.1002/mus.26608
doi: 10.1002/mus.26608
Alshehri A, Choksi R, Bucelli R, Pestronk A. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm 2015;2(4). doi:10.1212/NXI.0000000000000124
doi: 10.1212/NXI.0000000000000124
Pestronk A, Choksi R. Pathology features of immune and inflammatory myopathies, including a polymyositis pattern, relate strongly to serum autoantibodies. J Neuropathol Exp Neurol 2021;80(9):812–820. doi:10.1093/jnen/nlab071
doi: 10.1093/jnen/nlab071
Li X, Tan H. Value of 18F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis. Heliyon 2020;6(4):e03707. doi:10.1016/j.heliyon.2020.e03707
doi: 10.1016/j.heliyon.2020.e03707
Maliha PG, Hudson M, Abikhzer G, Singerman J, Probst S. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. Nucl Med Commun 2019;40(4):377–382. doi:10.1097/MNM.0000000000000981
doi: 10.1097/MNM.0000000000000981
Dalakas MC, Illa I, Dambrosia JM. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329(27):1993–2000. doi:10.1056/NEJM199312303292704
doi: 10.1056/NEJM199312303292704
Oddis CV, Reed AM, Aggarwal R. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65(2):314–324. doi:10.1002/art.37754
doi: 10.1002/art.37754
Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 1999;353(9166):1762–1763. doi:10.1016/S0140-6736(99)01927-3
doi: 10.1016/S0140-6736(99)01927-3
Barnes H, Holland AE, Westall GP. Cyclophosphamide for connective tissue disease-associated interstitial lung disease. Cochrane Database Syst Rev 2018;1(1). doi:10.1002/14651858.CD010908.pub2
doi: 10.1002/14651858.CD010908.pub2
Mann H, Vencovsky J. Clinical trials in myositis. Where do we stand? Curr Treat OptionsRheumatol 2021;7:222–242.
Dastmalchi M, Grundtman C, Alexanderson H. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67(12):1670–1677. doi:10.1136/ard.2007.077974
doi: 10.1136/ard.2007.077974
Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med 2015;373(17):1680–1682. doi:10.1056/NEJMc1506163
doi: 10.1056/NEJMc1506163
Aggarwal R, Bandos A, Reed AM. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66(3):740–749. doi:10.1002/art.38270
doi: 10.1002/art.38270
Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020;50(4):776–790. doi:10.1016/j.semarthrit.2020.03.007
doi: 10.1016/j.semarthrit.2020.03.007
Kao JC, Liao B, Markovic SN. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 2017;74(10):1216–1222. doi:10.1001/jamaneurol.2017.1912
doi: 10.1001/jamaneurol.2017.1912
Shelly S, Triplett JD, Pinto MV. Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun 2020;2(2). doi:10.1093/braincomms/fcaa181
doi: 10.1093/braincomms/fcaa181
Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep 2021;23(8). doi:10.1007/s11926-021-01023-9
doi: 10.1007/s11926-021-01023-9
Gokhale Y, Patankar A, Holla U. Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship?J Assoc Physicians India 2020;68(11):20–24.
Mehan WA, Yoon BC, Lang M. Paraspinal myositis in patients with COVID-19 infection. AJNR Am J Neuroradiol 2020;41(10):1949–1952. doi:10.3174/ajnr.A6711
doi: 10.3174/ajnr.A6711
Suh J, Mukerji SS, Collens SI. Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology 2021;97(8). doi:10.1212/WNL.0000000000012344
doi: 10.1212/WNL.0000000000012344
Aschman T, Schneider J, Greuel S. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol 2021;78(8):948–960. doi:10.1001/jamaneurol.2021.2004
doi: 10.1001/jamaneurol.2021.2004
Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med 2020;383(24):2389–2390. doi:10.1056/NEJMc2031085
doi: 10.1056/NEJMc2031085
Giannini M, Ohana M, Nespola B. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care?Eur Respir J 2020;56(3). doi:10.1183/13993003.01618-2020
doi: 10.1183/13993003.01618-2020
Gupta L, Lilleker JB, Agarwal V. COVID-19 and myositis—unique challenges for patients. Rheumatology (Oxford) 2021;60(2):907–910. doi:10.1093/rheumatology/keaa610
doi: 10.1093/rheumatology/keaa610
Živković SA, Gruener G, Narayanaswami P. AANEM Quality and Patient Safety Committee. Doctor-should i get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders. Muscle Nerve 2021;63(3):294–303. doi:10.1002/mus.27179
doi: 10.1002/mus.27179
N.I.H. COVID-19 Treatment Guidelines. Prevention of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/
N.I.H. COVID-19 Treatment Guidelines. Therapeutic Management of Nonhospitalized Adults With COVID-19. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/